Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Operations and Other Comprehensive Loss

v3.23.1
Condensed Consolidated Statement of Operations and Other Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 311,120 $ 266,446
Claims expense (283,906) (247,552)
Clinical care delivery expense (16,416) (23,927)
Platform & application expenses (8,594) (13,748)
Research & development expenses (4,476) (17,314)
Sales, general & administrative expenses (48,393) (55,649)
Premium deficiency reserve expense (2,494) (6,868)
Depreciation and amortization expenses (1,237) (3,078)
Loss from operations (54,396) (101,690)
Interest expense (8,819) (5,982)
Interest income 161 255
Gain on fair value remeasurement 336 78,773
Loss on settlement of warrants 155 0
Exchange loss (27) (447)
Loss on sale of subsidiary (646) 0
Net loss from operations before income taxes (63,236) (29,091)
Tax benefit / (provision) 7 (9)
Net loss (63,229) (29,100)
Other comprehensive loss    
Currency translation differences (565) (3,639)
Other comprehensive (loss), net of income tax (565) (3,639)
Total comprehensive loss $ (63,794) $ (32,739)
Net loss per share    
Net loss per share, basic, from continuing operations (in dollars per share) $ (2.53) $ (1.71)
Net loss per share, diluted, from continuing operations (in dollars per share) $ (2.53) $ (1.71)
Weighted average shares outstanding, basic (in shares) 25,025,645 17,038,663
Weighted average shares outstanding, diluted (in shares) 25,025,645 17,038,663